μλ―Έλ ΈμΉ΄νλ‘μ°
**μλ―Έλ ΈμΉ΄νλ‘μ°(EACA)**μ μλ―Έλ Έμ° λΌμ΄μ μ ν©μ± μ λ체μ λλ€. **μ¬μ μ μ©ν΄ μ΅μ μ ** λ° **νλ¨λ°±λΆν΄ν¨μ**λ‘ μμ©ν©λλ€. * **μμ¬μ μμνμ μ©λ**: κ°(νΉν μ λ¨Ό μ °νΌλ)μ **ν΄νμ± κ³¨μλ³μ¦(DM)**μ λν 보쑰 μΉλ£μ λ‘ μ¬μ©λμ΄ μμΌλ, νλμ μ¦κ±°λ μ΄ μ§νμ λν ν¨λ₯μ κ°ν μλ¬Έμ μ κΈ°ν©λλ€. μ°κ΅¬μ λ°λ₯΄λ©΄ μ κ²½νμ κ°μ μ΄ λνλμ§ μμμΌλ©°, DMμ λν μ¬μ©μ λμ²΄λ‘ μνμ μ΄κ³ ν¨κ³Όκ° μλ κ²μΌλ‘ κ°μ£Όλ©λλ€. * **μ£Όμ μμ μ©λ**: μ£Όμ κ·Όκ±° κΈ°λ° μ©λλ **κ³Όλ€ μ¬μ μ μ©ν΄λ‘ μΈν μΆν**μ κ΄λ¦¬μ λλ€. μμνμμλ μ€μ¦ μΆν μ₯μ , μΈμ λλ μμ μΆν(μ: μμ ν μ§μ° μΆν μμΈμ΄ μλ κ·Έλ μ΄νμ΄λ)μ μλ°©νκ±°λ μΉλ£νλ λ° μ μ λ λ§μ΄ μ¬μ©λκ³ μμ΅λλ€. * **νμν κ°μμ¦**: μΉλͺ μ μΈ μΆνμ μλ°©νκΈ° μν΄ κ°μ μ€μ¦ νμν κ°μμ¦μ λν 보쑰 μΉλ£μ λ‘ μ¬μ©νλ κ²μ λν κ΄μ¬μ΄ μ§μλκ³ μμΌλ, μμ μ±κ³Ό ν¨λ₯μ μμ§ μ‘°μ¬ μ€μ λλ€.
μμ© κΈ°μ : Aminocaproic acid is a lysine analog that competitively binds to the lysine-binding sites on **plasminogen**. * **Plasminogen** β (blocked by EACA) β Cannot bind to fibrin. * This prevents the conversion of plasminogen to **plasmin** by plasminogen activators. * At higher concentrations, it directly inhibits **plasmin** (antiplasmin activity), thereby preventing the breakdown of fibrin clots (**fibrinolysis**). * *In Degenerative Myelopathy*: It was theorized to exert **antiprotease activity**, reducing the activation of inflammatory enzymes that damage myelin, though clinical efficacy is lacking.
λλ¬Ό μ’ λ³ μ©λ
- Adjunctive treatment of degenerative myelopathy (seen primarily in German shepherds) Β· 500 mg/dog Β· PO Β· q8h Β· indefinitely Β· Used in conjunction with acetylcysteine at 25 mg/kg PO q8h for 2 weeks, then q8h every other day. The 20% solution should be diluted to 5% with chicken broth or suitable diluent. Other treatments may include prednisone, Vitamin C, and Vitamin E. Note: No treatment has been shown to be effective in published trials.
- Antifibrinolytic Β· 50-100 mg/kg Β· IV or PO Β· q6h Β· No published doses for dogs, but has been used anecdotally.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Active intravascular clotting (e.g., Disseminated Intravascular Coagulation - DIC)
μ΄μλ°μ
- GI irritation (vomiting, diarrhea) in ~1% of dogs
- Hyperkalemia (particularly in renal impaired patients)
μ½λ¬Ό μνΈμμ©
- Estrogens Β· Hypercoagulation states may occur in patients receiving aminocaproic acid and estrogens concurrently.
λͺ¨λν°λ§
- Serum potassium (especially in patients with preexisting renal failure)
- Signs of bleeding or thrombosis
- Neurological status (if used for degenerative myelopathy)
κ³Όμ©λ
> **Toxicity**: The intravenous lethal dose in dogs is reportedly **2.3 g/kg**. * **Clinical Signs**: At lower IV overdosages, **tonic-clonic seizures** were noted in some dogs. * **Treatment**: There is no known specific antidote, but the drug is dialyzable. Treatment should consist of supportive care and seizure management (e.g., diazepam, midazolam) if necessary.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.